Document Detail


Optimizing the treatment of hypertension and stable coronary artery disease: clinical evidence for fixed-combination perindopril/amlodipine.
MedLine Citation:
PMID:  19032136     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Optimized management of hypertension and coronary artery disease (CAD) improves cardiovascular risk and outcomes, and prevents complications. This article reviews evidence for the fixed combination of the angiotensin-converting enzyme (ACE) inhibitor perindopril and the calcium channel blocker amlodipine. METHODS: A literature search was performed in PubMed/MEDLINE to identify articles published in English between 1988 and March 2008 describing clinical trials, particularly outcome trials, or mechanisms of therapeutic action relevant to the use of combination therapy in patients with hypertension or stable coronary artery disease with an ACE inhibitor (perindopril) and a calcium channel blocker (amlodipine). FINDINGS: Clinical trials indicate that this combination may have a positive impact on cardiovascular mortality and morbidity in hypertensive individuals. The two complementary mechanisms of action appear to work in synergy, leading to more efficient blood pressure lowering, improved fibrinolytic function, and reduction of secondary effects. This also represents a simplified management strategy for stable CAD. Perindopril has proven efficacy in the prevention of cardiovascular events and mortality in CAD patients, while amlodipine is widely used in the symptomatic management of CAD. Both aspects of guideline-recommended management of CAD are therefore addressed in a single tablet. CONCLUSIONS: The clinical evidence for fixed-combination perindopril/amlodipine indicates it as a credible option for the optimization of the management of hypertension and CAD.
Authors:
Roberto Ferrari
Related Documents :
17307416 - Extent and distribution of coronary artery disease: a comparative study of invasive ver...
496636 - Routine coronary angiography prior to elective aortic reconstruction: results of select...
18344556 - Xenon or propofol anaesthesia for patients at cardiovascular risk in non-cardiac surgery.
6609076 - Segmental analysis of stress thallium myocardial emission tomography for localization o...
12507056 - Toxicologic myocardial sensitization.
9244216 - Intracoronary doppler assessment of moderate coronary artery disease: comparison with 2...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Review    
Journal Detail:
Title:  Current medical research and opinion     Volume:  24     ISSN:  1473-4877     ISO Abbreviation:  Curr Med Res Opin     Publication Date:  2008 Dec 
Date Detail:
Created Date:  2008-11-26     Completed Date:  2009-03-18     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0351014     Medline TA:  Curr Med Res Opin     Country:  England    
Other Details:
Languages:  eng     Pagination:  3543-57     Citation Subset:  IM    
Affiliation:
University of Ferrara, Italy and Fondazione Salvatore Maugeri IRCCS, Ferrara, Italy. fri@unife.it
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Amlodipine / administration & dosage*,  adverse effects
Angiotensin-Converting Enzyme Inhibitors / administration & dosage*,  adverse effects
Calcium Channel Blockers / administration & dosage*,  adverse effects
Clinical Trials as Topic
Coronary Artery Disease / drug therapy*,  mortality
Drug Combinations
Female
Humans
Hypertension / drug therapy*,  mortality
Male
Perindopril / administration & dosage*,  adverse effects
Practice Guidelines as Topic
Chemical
Reg. No./Substance:
0/Angiotensin-Converting Enzyme Inhibitors; 0/Calcium Channel Blockers; 0/Drug Combinations; 82834-16-0/Perindopril; 88150-42-9/Amlodipine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Comparison of efficacy and safety of ciprofloxacin otic solution 0.2% versus polymyxin B-neomycin-hy...
Next Document:  Economic evaluation of sorafenib in the treatment of hepatocellular carcinoma in Canada.